OWLSTONE MEDICAL LIMITED

• ◆

  Material uncertainty over going concern

  As stated in note 1, these events or conditions, along with the other matters as set forth in note 1, indicate that a material uncertainty exists that may cast significant doubt on the Group's and the parent Company's ability to continue as a going concern.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. OWLSTONE MEDICAL LIMITED 2016-03-04 → present
2. OWLSTONE LIMITED 2004-04-20 → 2016-03-04
3. TIGER DAWN LIMITED 2003-11-06 → 2004-04-20

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“As stated in note 1, these events or conditions, along with the other matters as set forth in note 1, indicate that a material uncertainty exists that may cast significant doubt on the Group's and the parent Company's ability to continue as a going concern.”

Group structure

1. OWLSTONE MEDICAL LIMITED · parent
   1. Omed Health Limited 100% · United Kingdom · Dormant company
   2. Owlstone Medical Inc. 100% · USA · Support services for sales and R&D

Significant events

• “A fundraising round completed in April 2025, raising a total of $29.9 million.”
• “The Group entered into a multi-year program in March 2025 with the Cystic Fibrosis Foundation, which made a $2.3 million equity investment.”
• “The largest program is POSEIDON, with Owlstone winning an award of up to $49.1 million in October 2025 from ARPA-H.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

15

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.